Zinc-alpha2-glycoprotein in patients with acute and chronic kidney disease

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Sörensen Zender, Inga ^a   Beneke, Jan ^a   Schmidt, Bernhard Mw ^a   Menne, Jan ^a   Haller, Hermann ^a   Schmitt, Roland ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute kidney injury; Adipokine; Hemodialysis; Zinc alpha2 glycoprotein

Indexed keywords

GLYCOPROTEIN; PLASMA PROTEIN; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

ARTICLE; BLOOD SAMPLING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; LABORATORY TEST; LIPID METABOLISM; RENAL REPLACEMENT THERAPY;

ACUTE KIDNEY INJURY; ADULT; AGED; BIOLOGICAL MARKERS; CARRIER PROTEINS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84880009100     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-145     Document Type: Article

References (26)

1. Zinc alpha 2-glycoprotein: a multidisciplinary protein. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F, Molecular cancer research: MCR 2008 6 6 892 906 10.1158/1541-7786.MCR-07-2195 18567794
2. Characterization of zinc-alpha(2)-glycoprotein as a cell adhesion molecule that inhibits the proliferation of an oral tumor cell line. Lei G, Brysk H, Arany I, Tyring SK, Srinivasan G, Brysk MM, J Cell Biochem 1999 75 1 160 169 10.1002/(SICI)1097-4644(19991001)75:1<160::AID-JCB16>3.0.CO;2-B 10462714
3. Zag expression during aging suppresses proliferation after kidney injury. Schmitt R, Marlier A, Cantley LG, Journal of the American Society of Nephrology: JASN 2008 19 12 2375 2383 10.1681/ASN.2008010035 18815245
4. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, Trayhurn P, FEBS Lett 2005 579 1 41 47 10.1016/j.febslet.2004.11.042 15620688
5. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Bing C, Bao Y, Jenkins J, Sanders P, Manieri M, Cinti S, Tisdale MJ, Trayhurn P, Proc Natl Acad Sci U S A 2004 101 8 2500 2505 10.1073/pnas.0308647100 14983038
6. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Russell ST, Zimmerman TP, Domin BA, Tisdale MJ, Biochim Biophys Acta 2004 1636 1 59 68 10.1016/j.bbalip.2003.12.004 14984739
7. Studies on the anti-obesity activity of zinc-alpha2-glycoprotein in the rat. Russell ST, Tisdale MJ, Int J Obes (Lond) 2011 35 5 658 665 10.1038/ijo.2010.193
8. Lipolysis is altered in MHC class I zinc-alpha(2)-glycoprotein deficient mice. Rolli V, Radosavljevic M, Astier V, Macquin C, Castan-Laurell I, Visentin V, Guigne C, Carpene C, Valet P, Gilfillan S, et al. FEBS Lett 2007 581 3 394 400 10.1016/j.febslet.2006.12.047 17234189
9. Determination of serum zinc-alpha-2-glycoprotein in patients with metabolic syndrome by a new ELISA. Stejskal D, Karpisek M, Reutova H, Stejskal P, Kotolova H, Kollar P, Clin Biochem 2008 41 4-5 313 316 18078816
10. Serum zinc-alpha2-glycoprotein correlates with adiposity, triglycerides, and the key components of the metabolic syndrome in Chinese subjects. Yeung DC, Lam KS, Wang Y, Tso AW, Xu A, J Clin Endocrinol Metab 2009 94 7 2531 2536 10.1210/jc.2009-0058 19351730
11. Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in preeclampsia. Stepan H, Philipp A, Roth I, Kralisch S, Jank A, Schaarschmidt W, Lossner U, Kratzsch J, Bluher M, Stumvoll M, et al. J Endocrinol Invest 2012 35 6 562 565 21791968
12. Serum adipokine zinc alpha2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, Montanari A, Regolisti G, Fiaccadori E, Cabassi A, Metab Clin Exp 2012 61 1 37 42 10.1016/j.metabol.2011.05.011 21696792
13. Zinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugs. Ceperuelo-Mallafre V, Escote X, Vilades C, Peraire J, Domingo P, Solano E, Sirvent JJ, Pastor R, Tinahones F, Leal M, et al. HIV Med 2012 13 5 297 303 10.1111/j.1468-1293.2011. 00976.x 22256965
14. Exploring metabolic dysfunction in chronic kidney disease. Slee AD, Nutr Metab 2012 9 1 36 10.1186/1743-7075-9-36
15. Is zinc-alpha2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DS, Junior ML, Mafra D, Clinica chimica acta; international journal of clinical chemistry 2012 413 5-6 616 619
16. Serum levels of the adipokine zinc-alpha2-glycoprotein are increased in chronic hemodialysis. Philipp A, Kralisch S, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M, Metab Clin Exp 2011 60 5 669 672 20708203
17. Zinc-alpha2-Glycoprotein: Is There Association between This New Adipokine and Body Composition in Hemodialysis Patients? Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Velarde GC, Fouque D, Leite M Jr, Mafra D, Ren Fail 2012 34 9 1062 1067 10.3109/0886022X.2012.712859 22906217
18. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, et al. BMJ 2012 345 4565 10.1136/bmj.e4565 22815429
19. Prospective evaluation of an in-centre conversion from conventional haemodialysis to an intensified nocturnal strategy. David S, Kumpers P, Eisenbach GM, Haller H, Kielstein JT, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 2009 24 7 2232 2240 10.1093/ndt/gfp029
20. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Levey AS, Stevens LA, American journal of kidney diseases: the official journal of the National Kidney Foundation 2010 55 4 622 627 10.1053/j.ajkd.2010.02.337
21. Renal handling of Zn-alpha2-glycoprotein as compared with that of albumin and the retinol-binding protein. Ekman R, Johansson BG, Ravnskov U, J Clin Invest 1976 57 4 945 954 10.1172/JCI108371 985827
22. Mechanisms of glomerular albumin filtration and tubular reabsorption. Tojo A, Kinugasa S, International journal of nephrology 2012 2012 481520 22685655
23. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K, J Clin Invest 2006 116 7 1784 1792 10.1172/JCI29126 16823476
24. Adipocytokines-novel link between inflammation and vascular function? Guzik TJ, Mangalat D, Korbut R, Journal of physiology and pharmacology: an official journal of the Polish Physiological Society 2006 57 4 505 528
25. Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, Ryden M, Arner P, Trayhurn P, Fearon KC, Bing C, Br J Cancer 2011 104 3 441 447 10.1038/sj.bjc.6606083 21245862
26. Role of beta-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-alpha2-glycoprotien (ZAG). Russell ST, Tisdale MJ, Biochim Biophys Acta 2012 1821 4 590 599 10.1016/j.bbalip.2011.12.003 22227600